Clinical trials
Homozygous Familial Hypercholesterolemia (HoFH) clinical trials
Below are recruiting homozygous familial hypercholesterolemia (hofh) clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07591298RecruitingPhase 2
SYH2070 injection for homozygous familial high cholesterol
This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.
Changsha, HunanAges 18 years+ - NCT06597006RecruitingPhase 3
Study of inclisiran for children with homozygous familial high cholesterol
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
San Francisco, CaliforniaAges 2–11 - NCT07491172RecruitingPhase 1
Trial of CTX310 for stubborn high cholesterol and fats
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
Hialeah, FloridaAges 18–75 - NCT04815005Recruiting
Registry study for people with HoFH
This study is a registry (a list that collects health information) for people with homozygous familial hypercholesterolemia, a genetic cholesterol condition. It helps researchers understand this condition better and connect patients with future research.
Philadelphia, PennsylvaniaAges Any age - NCT06597019RecruitingPhase 3
Study of inclisiran for children with high cholesterol
This trial tests a medicine called inclisiran to lower high cholesterol in children ages 6 to 12 with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It may help children who still have high cholesterol despite taking other treatments.
San Francisco, CaliforniaAges 6–11 - NCT01109368Recruiting
Registry for people with inherited very high cholesterol
This trial is a registry that collects information from people with homozygous familial hypercholesterolemia (an inherited condition causing extremely high “bad” cholesterol). It may help researchers better understand the condition and support future studies.
New York, New YorkAges Any age - NCT07447648Recruiting
Evinacumab for plaque buildup in HoFH
This observational study looks at how adding evinacumab to standard cholesterol-lowering therapy affects plaque in the heart arteries of people with homozygous familial hypercholesterolemia (HoFH). It compares those who started evinacumab within the last 2 years to those on standard therapy alone, using CT scans taken before and after treatment.
ParisAges 12 years+ - NCT07470723Recruiting
Familial Hypercholesterolemia in pregnancy and newborns study
This study looks at how familial hypercholesterolemia (a genetic condition that causes high cholesterol) affects mothers and their newborns. It aims to learn more about cholesterol levels during pregnancy and the baby's first week of life.
Madison, WisconsinAges 18 years+ - NCT07489209RecruitingPhase 2
Study of EDP167 for homozygous familial hypercholesterolemia
This trial tests a new drug, EDP167, for people with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes very high cholesterol. The goal is to see if EDP167 can lower 'bad' cholesterol (LDL-C).
BeijingAges 18 years+ - NCT05682378RecruitingPhase 3
Long-term follow-up for inclisiran in young people with inherited high cholesterol
This study follows people with HeFH or HoFH (inherited high cholesterol) who previously took inclisiran in specific pediatric ORION studies. It mainly checks long-term safety and how well the treatment continues to be tolerated over time.
Boca Raton, FloridaAges 12–100 - NCT06568471RecruitingPhase 3
Study of HST101 for high cholesterol in Chinese patients
This study tests a new injectable medication called HST101 for lowering cholesterol in people who are already taking cholesterol pills but still have high levels. It may help if you have heart disease or are at high risk.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Homozygous Familial Hypercholesterolemia (HoFH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for homozygous familial hypercholesterolemia (hofh)?
- Yes. Clin2 currently lists 11 recruiting homozygous familial hypercholesterolemia (hofh) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a homozygous familial hypercholesterolemia (hofh) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a homozygous familial hypercholesterolemia (hofh) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.